Dong Jingyan, Xu Yue, Yu Dawei, Zhang Xiaoling, Wang Anqi, Lv Lei, Li Zhiqing
Tianjin Key Laboratory of Retinal Functions and Diseases, Tianjin Branch of National Clinical Research Center for Ocular Disease, Eye Institute and School of Optometry, Tianjin Medical University Eye Hospital, Tianjin 300392, China; Shanxi Eye Hospital, Taiyuan 030001, China.
MOE Key Laboratory of Metabolism and Molecular Medicine, Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fudan University, Shanghai 200032, China; Obstetrics and Gynecology Hospital, Institute of Reproduction and Development, Fudan University, Shanghai 200032, China.
Eur J Cell Biol. 2024 Dec;103(4):151467. doi: 10.1016/j.ejcb.2024.151467. Epub 2024 Nov 14.
Uveal melanoma (UM) is the predominant form of eye cancer. The genes GNAQ and GNA11, encoding Gq and G11 respectively, are most frequently mutated in UM and are considered the major drivers of UM carcinogenesis by activating YAP. However, the mechanisms by which metastatic UM evades the immune system remain poorly understood. In this study, we found that oncogenic mutations of Gq/G11 promoted YAP and PD-L1 expression, modifying the tumor microenvironment and promoting immune evasion of UM. Consistently, the levels of GNAQ/GNA11 and YAP positively correlated to PD-L1 expression in UM patients. Furthermore, silencing YAP or treating with its inhibitor, Verteporfin, attenuated PD-L1 expression induced by Gq/G11 mutations, thereby enhancing T cell activation and T cell-mediated cytotoxicity. Collectively, this study reveals a potential role of Gq/G11 mutations on immune evasion of UM, a new mechanism of Gq/11 mutations-induced tumorigenesis, highlighting Gq/G11 and YAP as potential immunotherapeutic targets and suggesting Verteporfin as an adjuvant for immunotherapy of UM patients with GNAQ or GNA11 mutations.
葡萄膜黑色素瘤(UM)是眼癌的主要形式。分别编码Gq和G11的基因GNAQ和GNA11在UM中最常发生突变,并被认为是通过激活YAP驱动UM致癌的主要因素。然而,转移性UM逃避免疫系统的机制仍知之甚少。在本研究中,我们发现Gq/G11的致癌突变促进了YAP和PD-L1的表达,改变了肿瘤微环境并促进了UM的免疫逃逸。一致地,UM患者中GNAQ/GNA11和YAP的水平与PD-L1表达呈正相关。此外,沉默YAP或用其抑制剂维替泊芬治疗可减弱由Gq/G11突变诱导的PD-L1表达,从而增强T细胞活化和T细胞介导的细胞毒性。总体而言,本研究揭示了Gq/G11突变在UM免疫逃逸中的潜在作用,这是Gq/11突变诱导肿瘤发生的新机制,突出了Gq/G11和YAP作为潜在的免疫治疗靶点,并表明维替泊芬可作为GNAQ或GNA11突变的UM患者免疫治疗的佐剂。